Clinical Drug Development in Thromboembolic Diseases: Regulatory and Methodological Approach

E-ISSN： 1875-6220|9|2|105-118

ISSN： 1570-1638

Source： Current Drug Discovery Technologies, Vol.9, Iss.2, 2012-06, pp. : 105-118

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Issues for Clinical Drug Development in Neurodegenerative Diseases

By Dib Michel

Drugs, Vol. 65, Iss. 17, 2005-01 ,pp. : 2463-2479

Adis International

Access to resources Recommend Favorite

Advances in the approach to novel drug clinical development for breast cancer

By Ferrario Cristiano Batist Gerald

Expert Opinion on Drug Discovery, Vol. 9, Iss. 6, 2014-06 ,pp. : 647-668

Informa Healthcare

Access to resources Recommend Favorite

Regulatory Perspectives on Multiplicity in Adaptive Design Clinical Trials throughout a Drug Development Program

By Wang Sue-Jane

Journal of Biopharmaceutical Statistics, Vol. 21, Iss. 4, 2011-07 ,pp. : 846-859

Taylor & Francis Ltd

Access to resources Recommend Favorite

Drug Discovery and Development for Inflammatory Diseases

By Edwards III Carl K

Expert Opinion on Therapeutic Targets, Vol. 8, Iss. 2, 2004-04 ,pp. : 151-163

Informa Healthcare

Access to resources Recommend Favorite

Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis

By Dunkel Petra Chai Christina LL Sperlágh Beáta Huleatt Paul B Mátyus Péter

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 9, 2012-09 ,pp. : 1267-1308

Informa Healthcare

Access to resources Recommend Favorite